Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Biocytogen Signs Evaluation/Licensing Agreement for TCR-mimic with BioCopy

publication date: May 6, 2024

Beijing’s Biocytogen Pharmaceuticals signed a TCR-mimic antibody evaluation and potential licensing agreement with BioCopy AG of Basel, Switzerland. BioCopy will have access to fully human TCR-mimic antibodies targeting an intracellular antigen. The antibodies were generated by Biocytogen’s RenTCR-mimicTM mice. BioCopy, which will evaluate the TCR-mimic antibodies with an option to license them for novel cancer therapies, has an automated AI-based end-to-end platform that optimizes multispecific biotherapeutics to develop TCR-mimic antibodies into next-gen oncological drugs. More details....

Stock Symbol: (HK: 02315)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital